Oramed Pharmaceuticals Inc.: CFO Gabay Avraham sold 20,000 shares

What happened Gabay Avraham, CFO, sold 20,000 shares of Oramed Pharmaceuticals Inc. on Oct 01, 2026. The filing lists a weighted average price of $4.51 and total proceeds of $90,200.

Key details

• Transaction date and price: Oct 01, 2026; weighted average price $4.51; individual sale prices ranged from $4.440 to $4.650, inclusive (filing offers to provide breakdown on request).
• Transaction type: open market or private sale (code S).
• Shares owned after the transaction: not reported in the filing.
• Footnotes: F1 — shares sold pursuant to a Rule 10b5-1 trading plan adopted Mar 30, 2026. F2 — price is a weighted average; range provided $4.440 to $4.650 and the reporting person will provide per-price details on request.
• Filing date: Oct 02, 2026 (reporting period Oct 01, 2026).

Why it may matter

• The filing reports a sale of common stock under a Rule 10b5-1 plan, not an option exercise or a gift.
• The filing does not show why the insider traded or why the company acted.